NOTCH2 CONTRIBUTES TO VENETOCLAX RESISTANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA.

被引：0
|
作者：
Fiorcari, S. [1 ]
Maffei, R. [2 ]
Atene, C. G. [1 ]
Martinelli, S. [1 ]
Potenza, L. [1 ]
Luppi, M. [1 ]
Marasca, R. [1 ]
机构：
[1] Univ Modena & Reggio Emilia, Modena, Italy
[2] AOU Modena Policlin, Modena, Italy
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
C010
引用
收藏
页码：S28 / S29
页数：2
相关论文
共 50 条
  • [31] Venetoclax for the treatment of patients with chronic lymphocytic leukemia
    Crombie, Jennifer
    Davids, Matthew S.
    FUTURE ONCOLOGY, 2017, 13 (14) : 1223 - 1232
  • [32] Chronic lymphocytic leukemia that developes in a patient with chronic myeloid leukemia.
    Cacchione, R
    Gargallo, P
    Chena, C
    Slavutsky, I
    Dupont, J
    Riveros, D
    BLOOD, 2003, 102 (11) : 314B - 314B
  • [33] An update on the efficacy of Venetoclax for chronic lymphocytic leukemia
    Lovell, Alexandra R.
    Sawyers, Jacki
    Bose, Prithviraj
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (11) : 1307 - 1316
  • [34] Venetoclax Approved for Use in Chronic Lymphocytic Leukemia
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (05) : 339 - 339
  • [35] Emerging Data for Venetoclax in Chronic Lymphocytic Leukemia
    O'Brien, Susan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (03) : 178 - 183
  • [36] Venetoclax-Rituximab in Chronic Lymphocytic Leukemia
    Copur, Mehmet S.
    Gauchan, Dron
    Crockett, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22): : 2142 - +
  • [37] Patterns of Venetoclax Sensitivity in Chronic Lymphocytic Leukemia
    Dibb, James T.
    Long, Nicola
    Eide, Christopher A.
    Kurtz, Stephen E.
    Tognon, Cristina E.
    Tyner, Jeffrey W.
    Druker, Brian J.
    BLOOD, 2020, 136
  • [38] An update of venetoclax and obinutuzumab in chronic lymphocytic leukemia
    Salvaris, Ross
    Opat, Stephen
    FUTURE ONCOLOGY, 2020, 17 (04) : 371 - 387
  • [39] Evaluation of Cardiovascular Adverse Events Associated With Ibrutinib, Venetoclax and Idelalisib Used in Treatment of Chronic Lymphocytic Leukemia.
    Mahida, Hetavi
    Gharia, Bharatsinh
    Ugoeke, Nene
    Maludum, Obiora
    Asif, Arif
    Calderon, Dawn
    CIRCULATION, 2018, 138
  • [40] Aberrant NFAT2 signaling in chronic lymphocytic leukemia.
    Heitmann, Jonas S.
    Maerklin, Melanie
    Poljak, Alexandra
    Hackl, Bettina
    Stickel, Juliane
    Kanz, Lothar
    Kopp, Hans-Georg
    Wirths, Stefan
    Mueller, Martin Rudolf
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345